As he nears the end of the second year of his second stint leading the US Food and Drug Administration, one of the top priorities facing commissioner Robert Califf is the agency’s ongoing reorganization — the “biggest in the agency’s history” — which, Califf said, “will fundamentally change the way that we work.”
Califf discussed the reorganization, along with other topics of concern, during a webinar on 31 January hosted by the Alliance...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?